Education
About Us
Working with TipRanks
Follow Us
TNF Pharmaceuticals (TNFA)
NASDAQ:TNFA
TNFA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.33 - $3.50
Previous CloseN/A
Volume13.96K
Average Volume (3M)656.75K
Market Cap
$979.83K
Enterprise ValueN/A
Total Cash (Recent Filing)$225.66K
Total Debt (Recent Filing)$35.98K
Price to Earnings (P/E)―
Beta0.25
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.73
Shares Outstanding2,755,067
10 Day Avg. Volume215,911
30 Day Avg. Volume656,751
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
TNF Pharmaceuticals News
PremiumCompany Announcements
TNF Pharmaceuticals Discusses Isomyosamine Progress in Call
---
Ownership Overview
4.99%
Insiders
1.21% Mutual Funds
<0.01% Other Institutional Investors
93.29% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
TNFA FAQ
What was TNF Pharmaceuticals’s price range in the past 12 months?
TNF Pharmaceuticals lowest stock price was $0.33 and its highest was $3.50 in the past 12 months.
What is TNF Pharmaceuticals’s market cap?
TNF Pharmaceuticals’s market cap is $979.83K.
When is TNF Pharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were TNF Pharmaceuticals’s earnings last quarter?
TNF Pharmaceuticals released its earnings results on Apr 01, 2019. The company reported -$3.526 earnings per share for the quarter, missing the consensus estimate of N/A by -$3.526.
Is TNF Pharmaceuticals overvalued?
According to Wall Street analysts TNF Pharmaceuticals’s price is currently Overvalued.
Does TNF Pharmaceuticals pay dividends?
TNF Pharmaceuticals does not currently pay dividends.
What is TNF Pharmaceuticals’s EPS estimate?
TNF Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TNF Pharmaceuticals have?
TNF Pharmaceuticals has 2,755,067 shares outstanding.
What happened to TNF Pharmaceuticals’s price movement after its last earnings report?
TNF Pharmaceuticals reported an EPS of -$3.526 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of TNF Pharmaceuticals?
Currently, no hedge funds are holding shares in TNFA
---
Company Description
TNF Pharmaceuticals
TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
---
Technical Analysis
---